Cryo-Cell International (NYSEAMERICAN:CCEL – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported $0.07 earnings per share (EPS) for the quarter, FiscalAI reports. The company had revenue of $7.78 million during the quarter.
Cryo-Cell International Stock Up 5.3%
NYSEAMERICAN CCEL traded up $0.18 on Wednesday, hitting $3.58. 15,236 shares of the stock were exchanged, compared to its average volume of 12,349. Cryo-Cell International has a fifty-two week low of $2.72 and a fifty-two week high of $5.43. The company has a 50-day moving average price of $3.52 and a 200-day moving average price of $3.45. The company has a market cap of $28.85 million, a PE ratio of -10.85 and a beta of 0.49.
Hedge Funds Weigh In On Cryo-Cell International
An institutional investor recently bought a new stake in Cryo-Cell International stock. Susquehanna International Group LLP purchased a new position in shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL – Free Report) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 11,062 shares of the company’s stock, valued at approximately $51,000. Susquehanna International Group LLP owned about 0.14% of Cryo-Cell International at the end of the most recent reporting period. 10.44% of the stock is currently owned by institutional investors.
About Cryo-Cell International
Cryo-Cell International, Inc is a pioneering provider of umbilical cord blood and tissue preservation services. Headquartered in Oldsmar, Florida, the company was founded in 1989 as the first private cord blood bank in the United States. Cryo-Cell operates FDA-registered and AABB-accredited laboratory facilities, maintaining stringent quality control measures and cryogenic storage systems to safeguard stem cell viability over long-term storage periods.
The company’s primary business activity centers on the collection, processing and secure storage of newborn stem cell sources harvested at birth.
Recommended Stories
- Five stocks we like better than Cryo-Cell International
- Why Johnson & Johnson’s Earnings Dip Looks Like a Buying Opportunity
- CPI Comes In Cool: Why It Could Revive These 3 Rate-Sensitive Stocks
- Why ASML’s AI Monopoly Is Still Getting Stronger
- Apple’s AI Toll Booth Thesis Faces Its Biggest Test Yet Before Earnings
Receive News & Ratings for Cryo-Cell International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryo-Cell International and related companies with MarketBeat.com's FREE daily email newsletter.
